{"id":"genetically-attenuated-pfspz-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reactions"},{"rate":"null","effect":"Fever"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This vaccine uses a genetically modified form of the parasite to induce a protective immune response, which can help prevent malaria infection. The weakened parasite is designed to mimic the natural infection process, but with reduced severity, allowing the immune system to develop a targeted response without causing disease.","oneSentence":"The Genetically attenuated PfSPZ Vaccine works by introducing a weakened form of the Plasmodium falciparum parasite to stimulate an immune response against malaria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:38:12.421Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of malaria"}]},"trialDetails":[{"nctId":"NCT06735209","phase":"PHASE1","title":"First-in-Human PfSPZ-LARC2 Vaccination/CHMI","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-23","conditions":"Malaria","enrollment":22},{"nctId":"NCT07385287","phase":"PHASE2","title":"Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults","status":"NOT_YET_RECRUITING","sponsor":"Sanaria Inc.","startDate":"2026-04-04","conditions":"Malaria (Plasmodium Falciparum)","enrollment":180},{"nctId":"NCT03163121","phase":"PHASE1","title":"Safety and Protective Efficacy of Genetically Attenuated PfSPZ-GA1 Vaccine in Healthy Dutch Volunteers","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2017-05-12","conditions":"Malaria","enrollment":67}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Genetically attenuated PfSPZ Vaccine","genericName":"Genetically attenuated PfSPZ Vaccine","companyName":"Sanaria Inc.","companyId":"sanaria-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"The Genetically attenuated PfSPZ Vaccine works by introducing a weakened form of the Plasmodium falciparum parasite to stimulate an immune response against malaria. Used for Prevention of malaria.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}